Quark Delayed Graft Function Drug Safe in Phase I | GenomeWeb

Quark Pharmaceuticals this week announced the release of phase I data showing its delayed graft function prophylaxis QPI-1002 to be safe in kidney transplant recipients.

QPI-1002, which is designed to silence p53, was tested in 40 transplant recipients of kidneys from deceased donors. Safety data show no dose-limiting toxicities in any cohort, Quark said, supporting the drug's continued development.

The full data from the study are currently under analysis, the company added.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.